

TANZANIA

Support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme

1. Country: Tanzania			
2. Grant number: 16-TZA-12c-X			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 01 July 20113			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration⁶: 2012 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2012-2015	2016	Total ⁷
Programme budget (US\$)	US\$95,853,321 ⁸	US\$23,205,500	US\$119,058,821
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of Pneumococcal vaccines doses		4,631,400	
Number of AD syringes		5,101,100	
Number of safety boxes		56,125	
Annual amounts (US\$)	US\$95,853,321 ¹⁰	US\$23,205,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-TZA-12c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	275,400
Value of vaccine doses (US\$)	US\$924,939
Total co-financing payments (US\$) (including freight)	US\$981,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

TANZANIA Support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme

1. Country: Tanzania			
2. Grant number: 16-TZA-04c-X			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 01 July 2013			
5. Programme title: New vaccine support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration¹¹: 2009 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2009-2015	2016	Total ¹²
Programme budget (US\$)	US\$76,920,813 ¹³	US\$11,318,000	US\$88,238,813
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2009-2015	2016	
Number of Pentavalent vaccines doses		5,975,500	
Number of AD syringes		6,727,900	
Number of safety boxes		74,025	
Annual amounts (US\$)	US\$76,920,813 ¹⁵	US\$11,318,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the programme.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-TZA-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	730,500
Value of vaccine doses (US\$)	US\$1,312,329
Total co-financing payments (US\$) (including freight)	US\$1,341,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

TANZANIA Support for Rotavirus vaccine

This decision letter sets out the programme terms of a programme

1. Country: Tanzania			
2. Grant number: 16-TZA-13b-X			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 01 July 2013			
5. Programme title: New vaccine support (NVS), Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme duration¹⁶: 2013 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2013-2015	2016	Total ¹⁷
Programme budget (US\$)	US\$29,670,198 ¹⁸	US\$7,724,500	US\$37,394,698
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ¹⁹			
Type of supplies to be purchased with Gavi funds in each year	2013-2015	2016	
Number of Rotavirus vaccines doses		3,418,500	
Annual amounts (US\$)	US\$29,670,198 ²⁰	US\$7,724,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹⁶ This is the entire duration of the programme.

¹⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

¹⁸ This is the consolidated amount for all previous years.

¹⁹ This is the amount that Gavi has approved.

²⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-TZA-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	333,000
Value of vaccine doses (US\$)	US\$730,575
Total co-financing payments (US\$) (including freight)	US\$750,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
 Managing Director, Country Programmes
 18 November 2015